Early Experience of Localized Prostate Cancer Treated with Neoadjuvant Androgen Ablation Therapy and Radiotherapy.
- Author:
Ok Hyun CHIN
1
;
Sun Il KIM
;
Sung Joon HONG
Author Information
1. Department of Urology, Yonsei University College of Medicine, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Radiotherapy;
Neoadjuvant androgen deprivation;
Prostate cancer
- MeSH:
Dysuria;
Follow-Up Studies;
Humans;
Lymph Nodes;
Neoplasm Metastasis;
Proctitis;
Prostate*;
Prostatic Neoplasms*;
Radiotherapy*;
Recurrence;
Urethral Stricture
- From:Korean Journal of Urology
2001;42(7):702-706
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: We investigated the trends and results of the outcome in patients with localized and locally advanced prostatic cancer treated with neoadjuvant androgen deprivation (NAAD) and external beam radiotherapy. MATERIALS AND METHODS: 14 patients with localized prostate cancer were treated with a 4 month-scheduled treatment that consisted of NAAD and radiotherapy. The number of patients in the clinical stage T1, T2, T3, and T4 were 3, 5, 2, and 4, respectively. External beam radiotherapy was performed for 6 weeks during NAAD period. After treatment, PSA relapse was evaluated with periodic PSA follow-up. RESULTS: There was no lymph node or distant metastasis in 14 patients. In all cases, PSA was less than 1ng/ml within 3 months of treatment. The number of patients with Gleason scores 2-4, 5-7 and 8-10 were 1, 7, and 4, respectively. In only one case with preradiotherapy PSA nadir level of 0.23ng/ml, the rising PSA level (>2.5ng/ml) was observed at 6 months after the end of the treatment, and the androgen deprivation resumed 10 months after the end of the treatment. No severe complication was observed in all patients, and the observed minor complications were dysuria (3; 21.4%), frequency (2; 14.3%), urgency (1; 7.1%), urethral stricture (1; 7.1%), proctitis (2; 14.3%) and gastrointestinal discomfort (1; 7.1%). CONCLUSIONS: In patients treated with NAAD and radiation therapy for localized or locally confined prostate carcinoma, generally good responses were observed. No se vere complication was observed and more patients and follow up are required for the further conclusion.
